You are here

cemiplimab

Sanofi says on track to regain solid position in cancer drugs

Sanofi says on track to regain solid position in cancer drugs

Reuters

molecular oncology

Flag link:

5 takeaways from the first look at cancer's biggest conference

5 takeaways from the first look at cancer's biggest conference

Biopharma Dive

Bristol-Myers Squibb

Jounce Therapeutics

Flag link:

Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint

Regeneron/Sanofi circle October 28 on the calendar as the FDA begins a speedy review of the world’s 6th PD-1/L1 checkpoint

Endpoints

PD-1 inhibitors

Flag link:

Regeneron’s coming late to a group of drugs that’s already worth billions — here’s why the company thinks it can still compete

Regeneron’s coming late to a group of drugs that’s already worth billions — here’s why the company thinks it can still compete

SF Gate, CA

PDL-1 inhibitors

Flag link:

Sanofi and Regeneron boost investment in cancer drug cemiplimab

Sanofi and Regeneron boost investment in cancer drug cemiplimab

Yahoo/Reuters

Flag link:

On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo

On a new deal spree, Regeneron buys into ISA in pursuit of a checkpoint combo

Endpoints

cervical cancer

head and neck cancer

Flag link:

Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?

Will This Drug Kick-Start Regeneron Pharmaceuticals Shares?

Motley Fool

Flag link:

Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd?

Regeneron, Sanofi are ready to debut the 6th PD-1/L1. Is it still possible to stand out from the growing crowd?

Endpoints

advanced cutaneous squamous cell carcinoma

Flag link:

Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance

Sanofi, Regeneron earn ‘breakthrough’ status for a fast-track drug out to prove PD-1 dominance

Endpoints

breakthrough status

Flag link: